Journal Article

Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer

Gilleryd, M, von Plessen, C, Sundstrøm, S, Stephens, R, Vilsvik, J, Bremnes, R M, Aasebø, U, Sörenson, S, Bergman, B, Andresen, O

2006

Overview

This randomised multicentre trial was conducted to establish the optimal duration of palliative chemotherapy in advanced non-small-cell lung cancer (NSCLC). We compared a policy of three vs six courses of new-generation platinum-based combination chemotherapy with regard to effects on quality of life (QoL) and survival. Patients with stage IIIB or IV NSCLC and WHO performance status (PS) 0–2 were randomised to receive three (C3) or six (C6) courses of carboplatin (area under the curve (AUC) 4, Chatelut's formula, equivalent to Calvert's AUC 5) on day 1 and vinorelbine 25 mg m −2 on days 1 and 8 of a 3-week cycle. Key end points were QoL at 18 weeks, measured with EORTC Quality of Life Questionnaire (QLQ)-C30 and QLQ-LC13, and overall survival. Secondary end points were progression-free survival and need of palliative radiotherapy. Two hundred and ninety-seven patients were randomised (C3 150, C6 147). Their median age was 65 years, 30% had PS 2 and 76% stage IV disease. Seventy-eight and 54% of C3 and C6 patients, respectively, completed all scheduled chemotherapy courses. Compliance with QoL questionnaires was 88%. There were no significant group differences in global QoL, pain or fatigue up to 26 weeks. The dyspnoea palliation rate was lower in the C3 arm at 18 and 26 weeks ( P <0.05), but this finding was inconsistent across different methods of analysis. Median survival in the C3 group was 28 vs 32 weeks in the C6 group ( P =0.75, HR 1.04, 95% CI 0.82–1.31). One- and 2-year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6 arm, respectively. Median progression-free survival was 16 and 21 weeks in the C3 and C6 groups, respectively ( P =0.21, HR 0.86, 95% CI 0.68–1.08). In conclusion, palliative chemotherapy with carboplatin and vinorelbine beyond three courses conveys no survival or consistent QoL benefits in advanced NSCLC.

• Publisher: Nature Publishing Group UK,Nature Publishing Group
• Subject: 80 and over / Adult / Aged / Aged, 80 and over / Antineoplastic Combined Chemotherapy Protocols - administration & dosage / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Antineoplastic Combined Chemotherapy Protocols/administration / Biological and medical sciences / Biomedical and Life Sciences / Biomedicine / Cancer Research / Carboplatin - administration & dosage / Carboplatin - adverse effects / Carboplatin/administration & dosage/adverse effects / Carcinoma / Carcinoma, Non-Small-Cell Lung - drug therapy / Carcinoma, Non-Small-Cell Lung - mortality / Carcinoma, Non-Small-Cell Lung - pathology / Clinical Study / dosage/adverse effects/therapeutic use / Drug Administration Schedule / Drug Resistance / Epidemiology / Fatigue - chemically induced / Female / Follow-Up Studies / Humans / Lung cancer / Lung Neoplasms - drug therapy / Lung Neoplasms - mortality / Lung Neoplasms - pathology / Lung Neoplasms/drug therapy/mortality/pathology / Lungmedicin och allergi / Male / Medical sciences / MEDICIN / MEDICINE / Middle Aged / Molecular Medicine / Neoplasm Staging / Non-Small-Cell Lung/drug therapy/mortality/pathology / Oncology / Pain - chemically induced / Palliative Care / Pneumology / Quality of Life / Questionnaires / Respiratory Medicine and Allergy / Surveys and Questionnaires / Survival Analysis / Survival Rate / Time Factors / Treatment Outcome / Tumors / Tumors of the respiratory system and mediastinum / Vinblastine - administration & dosage / Vinblastine - adverse effects / Vinblastine - analogs & derivatives / Vinblastine/administration & dosage/adverse effects/analogs & derivatives / Vinorelbine